Skip to main content

Dexcom cash and equivalents

  • DXCM · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B

Dexcom's cash and equivalents was $918 million for fiscal year 2025 (the twelve months to 31 Dec 2025), up 51.4% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was $961 million, down 47.6% from a year earlier.

From Dexcom's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.

Fiscal 2025
$918M
+51.4%
Q3 FY2026
$961M
−47.6% on a year
Growth over 9 years
+28.7%
a year, FY 2016–FY 2025

Cash and equivalents by fiscal year

$94.5MFY 2016$442MFY 2017+367%$1.14BFY 2018+158%$446MFY 2019−60.8%$818MFY 2020+83.2%$1.05BFY 2021+28.7%$642MFY 2022−39.0%$566MFY 2023−11.8%$606MFY 2024+7.0%$918MFY 2025+51.4%

Change on the year before, under each year. From FY 2016 to FY 2025, Dexcom's cash and equivalents went from $94.5 million to $918 million, a compound annual change of +28.7%; the highest was $1.14 billion in FY 2018.

Dexcom cash and equivalents, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$94.5M$442M$1.14B$446M$818M$1.05B$642M$566M$606M$918M
Period end31 Dec 201631 Dec 201731 Dec 201831 Dec 201931 Dec 202031 Dec 202131 Dec 202231 Dec 202331 Dec 202431 Dec 2025

Cash and equivalents by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Dexcom cash and equivalents, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Cash and equivalents$606M$905M$1.16B$1.84B$918M$1.12B$1.10B$961M
Period end31 Dec 202431 Mar 202530 Jun 202530 Sep 202531 Dec 202531 Mar 202630 Jun 202630 Sep 2026

How cash and equivalents is measured

Cash and equivalents is the cash the company holds at the end of the period and the investments it can turn into cash within three months. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Dexcom's other figures

Cash and equivalents of comparable companies

Everything on DXCM, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.